ROCKVILLE, Md. — October 30, 2025 — Leads & Copy — Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) will participate in investor conferences in November 2025.
Ascentage Pharma’s management will attend the Goldman Sachs APAC Healthcare Corporate Day on November 5, holding one-on-one and group investor meetings. Additionally, the company will present at the Stifel 2025 Healthcare Conference on November 13 at 2:40 pm EST.
Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company focused on novel therapies for unmet medical needs in cancer. Its pipeline includes inhibitors targeting apoptotic pathway proteins and next-generation kinase inhibitors.
Olverembatinib, the company’s first approved product, is a third-generation BCR-ABL1 inhibitor for chronic myelogenous leukemia (CML) treatment in China. Lisaftoclax, its second approved product, treats hematologic malignancies and is approved in China for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients who have received prior systemic therapy.
Ascentage Pharma collaborates with companies like Takeda, AstraZeneca, Merck, Pfizer, and Innovent, and research institutions including Dana-Farber Cancer Institute and Mayo Clinic.
Investor Relations:
Hogan Wan, Head of IR and Strategy
Hogan.Wan@ascentage.com
+86 512 85557777
Stephanie Carrington
AscentageIR@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Jon Yu
AscentagePR@icrhealthcare.com
+1 (646) 677-1855
Source: Ascentage Pharma Group International
